skip to main content

Bevacizumab Ovarian Maintenance — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardGynaecological CancersBevacizumab Ovarian MaintenanceSCE Medical Oncology

A patient with newly diagnosed advanced high-grade serous ovarian cancer has a BRCA1 pathogenic variant and responds to platinum chemotherapy. Which factor is central to selecting maintenance treatment?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — BRCA/HRD status, prior treatment and medicine-specific NICE eligibility

Ovarian-cancer maintenance is biomarker and treatment-pathway specific. BRCA or homologous-recombination status, response to platinum, whether bevacizumab formed part of first-line therapy, contraindications and current NICE technology-appraisal eligibility determine the appropriate PARP-inhibitor or combination strategy.

Reference: https://www.nice.org.uk/guidance/conditions-and-diseases/cancer